UNSPSC 51191920: Niacinamide or nicotinamide

This classification denotes a b vitamin with the molecular formula C6H6N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25X51I8RD4, chemically known as pyridine, 3-carbamoyl- but generally known as niacinamide, which bears US NIH Compound Identifier 936. European Medicines Agency schedules Niacinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20661. The term NICOTINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3).

UNSPSC 51191920 Niacinamide or nicotinamide is a Commodity code covering chemical supply for state and local government operations, though recent solicitations show activity in tangentially related chemical commodities rather than niacinamide specifically. State and local issuing bodies soliciting under this code span municipal water utilities, state health and human services departments, and multistate cooperative purchasing alliances. The work involves procurement of chemical products for facility operations—water treatment chemicals for municipal pollution control facilities and pharmaceutical active ingredients and over-the-counter products for health and welfare distribution networks. Suppliers typically compete on unit cost and pricing format flexibility, and must meet federal quality compliance standards (cGMP, DSCSA, FDA) and maintain substantial liability coverage with performance bonds where applicable.

Recent activity appears concentrated in the Upper Midwest. The City of Meriden, Connecticut issued IFB B027-15 for sodium bisulfite chemical supply to its Water Pollution Control Facility, with bids due July 29, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 to establish multiple contracts for generic pharmaceuticals and OTC products, with a proposal deadline of March 26, 2026 and anticipated contract effectiveness of July 1, 2026. MMCAP's RFP required vendors to submit detailed product specifications (NDC codes, SKUs, UPCs, strength, dosage form, packaging) and accept authorized wholesaler distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with pricing weighted at 75 percent of evaluation and a 3 percent administrative fee imposed on all contract purchases.